Evidence map›Paper›PMID 37999238›Full record

ArticleMetabolites2023

Metabolomics Analysis of Mesenchymal Stem Cell (MSC) Therapy in a Phase I Clinical Trial of Septic Shock: An Exploratory Study.

Mohammad M Banoei, Lauralyn A McIntyre, Duncan J Stewart, Shirley H J Mei, David Courtman, Irene Watpool, John Granton, John Marshall, Claudia Dos Santos, Keith R Walley and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Mohammad M BanoeiDepartment of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4Z6, Canada.
Lauralyn A McIntyreDepartment of Medicine (Division of Critical Care), University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Duncan J StewartOttawa Hospital Research Institute, Ottawa, ON K1H 8M5, Canada.
Shirley H J MeiOttawa Hospital Research Institute, Ottawa, ON K1H 8M5, Canada.
David CourtmanOttawa Hospital Research Institute, Ottawa, ON K1H 8M5, Canada.
Irene WatpoolOttawa Hospital Research Institute, Ottawa, ON K1H 8M5, Canada.
John GrantonDepartment of Medicine, University of Toronto, Toronto, ON M5G 2N2, Canada.
John MarshallDepartment of Surgery and Critical Care Medicine, Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, The University of Toronto, Toronto, ON M5B 1W8, Canada.
Claudia Dos SantosDepartment of Surgery and Critical Care Medicine, Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, The University of Toronto, Toronto, ON M5B 1W8, Canada.
Keith R WalleyCentre for Heart Lung Innovation, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.
Kenny SchlosserOttawa Hospital Research Institute, Ottawa, ON K1H 8M5, Canada.
Dean A FergussonOttawa Hospital Research Institute, Ottawa, ON K1H 8M5, Canada.
Brent W WinstonDepartment of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4Z6, Canada.ORCID 0000-0003-2993-8871
On Behalf Of Canadian Critical Care Trials Group Ccctg
On Behalf Of Canadian Critical Care Translational Biology Group Ccctbg
Ottawa Hospital · CAUniversity of Ottawa · CASt. Michael's Hospital · CAUniversity of Calgary · CAUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is the result of an uncontrolled host inflammatory response to infection that may lead to septic shock with multiorgan failure and a high mortality rate. There is an urgent need to improve early diagnosis and to find markers identifying those who will develop septic shock and certainly a need to develop targeted treatments to prevent septic shock and its high mortality. Herein, we explore metabolic alterations due to mesenchymal stromal cell (MSC) treatment of septic shock. The clinical findings for this study were already reported; MSC therapy was well-tolerated and safe in patients in this phase I clinical trial. In this exploratory metabolomics study, 9 out of 30 patients received an escalating dose of MSC treatment, while 21 patients were without MSC treatment. Serum metabolomics profiling was performed to detect and characterize metabolite changes due to MSC treatment and to help determine the sample size needed for a phase II clinical trial and to define a metabolomic response to MSC treatment. Serum metabolites were measured using

Indexed as

biomarkercell therapyclinical trialmesenchymal stem cellsmetabolomicsseptic shock

Identifiers

PMID37999238
PMCPMC10673547
OpenAlexW4388636018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.